1Cell.Ai Revolutionizes Cancer Diagnostics with OncoIncytes for Precision Oncology

1Cell.Ai Revolutionizes Cancer Diagnostics

In a remarkable leap forward in the field of cancer diagnostics, 1Cell.Ai, formerly OneCell Diagnostics, has launched OncoIncytes, a sophisticated multi-modal diagnostic panel designed to revolutionize the approach to precision oncology. This innovative technology integrates a variety of data types, including Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) at single-cell resolution, RNA transcriptomics, and proteomics, all of which work synergistically to provide oncologists with an unprecedented level of insight.

Mohan Uttarwar, the CEO and co-founder of 1Cell.Ai, emphasizes the significance of OncoIncytes in enhancing the clinical decision-making process. As the company transitions from a purely genomics-based diagnostic approach to an AI-driven powerhouse in precision oncology, the integration of diverse data forms a crucial part of this evolution. The OncoIncytes platform not only optimizes patient selection for clinical trials—especially those involving antibody-drug conjugates—but also enhances the success rates of these studies through exceptional sensitivity and specificity.

The Technology Behind OncoIncytes

The cutting-edge technology of OncoIncytes utilizes a comprehensive 1080 gene panel combined with advanced AI and machine learning to elucidate complex clinical narratives. It allows for the detection of specific protein expressions on cell surfaces that are often missed by traditional liquid biopsy tests. This newfound capability marks a significant stride in cancer research, facilitating drug development, patient identification, and therapy response monitoring with remarkable granularity.

Healthcare providers can now streamline the diagnostic process by requesting sample collection kits, which are dispatched to the 1Cell.Ai laboratory from hospitals and clinical trial sites. Upon collection, the team at 1Cell.Ai meticulously processes the data and swiftly uploads the results via their iDiscover application, ensuring maximum accuracy. Notably, the Foster City laboratory has recently received CLIA certification, further validating its commitment to high-quality diagnostics.

In terms of validation, the 1080 gene panel demonstrated total concordance when tested against established methodologies, such as Illumina's TSO 500 and an FDA-cleared PGDx panel, validating its reliability and effectiveness.

Commitment to Accessible Oncology

Uttarwar further underscores the company's mission to democratize precision oncology. By making advanced diagnostic testing more accessible, actionable, and cost-effective, the rebranding to 1Cell.Ai encapsulates its expanded vision of transforming cancer care through the application of artificial intelligence. The firm aims to go beyond mere diagnostic solutions and establish a more comprehensive platform for AI-powered precision oncology.

This major technological leap coincides with a recently oversubscribed $16 million Series A funding round. Additionally, the formation of an esteemed clinical advisory board of global cancer experts, chaired by Nobel Laureate Dr. James Rothman, showcases the firm’s commitment to advancing cancer research and treatment.

A New Era in Cancer Care

As 1Cell.Ai steps into this new chapter, the launch of OncoIncytes represents not just a technological advancement but a transformative approach to how clinicians will diagnose and treat cancer in the future. With its comprehensive multi-modal capabilities and a focus on using AI to enhance clinical outcomes, 1Cell.Ai is set to redefine the standards of precision oncology, ultimately offering hope to countless patients worldwide who are battling this formidable disease.

For more information about OncoIncytes and the transformative work of 1Cell.Ai, visit www.1Cell.Ai.